Eculizumab (anti-Complement C5) (C007B-327699)

Eculizumab (anti-Complement C5) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab (anti-Complement C5) inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab (anti-Complement C5) has the potential for haemolysis research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg. Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot PubChem CID: 3081333 Isomeric SMILES: CCCC[C@H](C(=O)O)N(C(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC)N)C(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](CCC[C@@H]3C)C

UPC:

51202408

Condition:

New

Weight:

1.09 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

Ab170870-5mg

CAS:

219685-50-4

Product Size:

5mg